Please assess the completion status of the following clinical trial:

Trial Title: RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed cutaneous T-cell non-Hodgkin lymphoma (CTCL)~* Relapsed or refractory disease, meeting 1 of the following criteria:~  * Progression of disease following 2 prior chemotherapies~ * Failure to respond to the second prior chemotherapy~* Measurable disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 3 months~* Serum creatinine \< 1.5 times upper limit of normal (ULN)~* Serum AST/ALT \< 2.5 times ULN~* Total bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL in patients with Gilbert syndrome)~* WBC count ≥ 3,000/mm³~* Platelet count ≥ 100,000/mm³~* Serum albumin \> 2.5 g/dL~* LVEF ≥ 45% by 2-D ECHO or MUGA scan~* Human antimurine antibody \< 1 μg/mL~* Patients with a history of electrocardiogram abnormalities, symptoms of cardiac ischemia, or arrhythmias must have a normal cardiac stress test (i.e., stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test)~* Must be willing to undergo venipuncture and central line placement~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No HBV surface antigen, HCV, or HIV antibody positivity~* No autoimmune disease or immunodeficiency (i.e., HIV)~* No history of uncontrolled concurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Ongoing or active cardiac disease (i.e., congestive heart failure, unstable angina pectoris, or cardiac arrhythmia)~ * Psychiatric illness and/or social situation that would preclude study compliance~* No other malignancies except treated basal cell or squamous cell carcinoma of the skin, or treated carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 3 weeks since prior systemic therapy for CTCL~* More than 6 months since prior chronic steroid therapy or chronic anti-coagulation therapy~* No prior therapy with anti-CD25 immunotoxin IMTOX25 and/or Ontak~* No other concurrent cancer chemotherapy, experimental therapy, investigational agent, or immunomodulating agent (including steroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- IMTOX25 at 2mg/m²/dose (Type: EXPERIMENTAL): Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.

Based on this trial design, predict the completion outcome and termination type (if applicable).